Hope for thousands with haemophilia in form of new injection
Trials of fitusiran, found it stopped bleeds in up to two-thirds (66 per cent) of patients with haemophillia A or B. Experts say the preventative treatment could soon improve patients' daily lives (Source: the Mail online | Health)
Source: the Mail online | Health - March 30, 2023 Category: Consumer Health News Source Type: news
Can motor proficiency testing predict sports injuries and sports-induced bleeds in people with haemophilia? - Versloot O, Blokzijl J, Timmer M, Schuuring M, van Galen K, Kremer Hovinga I, van der Valk P, van Vulpen L, Schutgens R, van Koppenhagen C, van der Net J, Fischer K.
INTRODUCTION: Predicting the risk of sports injuries and sports-induced bleeds (SIBs) in people with haemophilia (PWH) may support clinical counselling. AIM: To assess the association between motor proficiency testing and sports injuries and SIBs a... (Source: SafetyLit)
Source: SafetyLit - March 9, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Local Partnership Launches Digital Health Tool to Decrease Hypertension in Senegal
March 08, 2023Saytu Tension—a suite of digital solutions that will help accelerate early detection, linkage to care, and follow-up among hypertensive patients in Senegal—launched on January 27 in Dakar.As part of theCARDIO4Dakar project, funded by the Novartis Foundation and implemented by IntraHealth International in partnership with the Senegalese Ministry of Health and Social Action, Saytu Tension (“check your blood pressure” in Wolof) will amplify existing efforts to reach more people with information about cardiovascular risk factors, such as hypertension, and help link clients to diagnosis and...
Source: IntraHealth International - March 8, 2023 Category: International Medicine & Public Health Authors: kseaton Tags: Senegal CARDIO4Dakar Noncommunicable Diseases Digital Health Source Type: news
Benefits of Valoctocogene Roxaparvovec Persist in Hemophilia A
FRIDAY, March 3, 2023 -- For patients with hemophilia A, factor VIII activity and bleeding reduction persist at two years after gene transfer with valoctocogene roxaparvovec, which delivers a B-domain-deleted factor VIII coding sequence with an... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 3, 2023 Category: Pharmaceuticals Source Type: news
Gene Therapy Beneficial for Patients With Hemophilia B
FRIDAY, March 3, 2023 -- For patients with hemophilia B, one infusion of adeno-associated virus 5 (AAV5) vector expressing the Padua factor IX variant (etranacogene dezaparvovec) is noninferior and superior to prophylaxis with factor IX, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 3, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Once-Weekly Product for Hemophilia A FDA Approves Once-Weekly Product for Hemophilia A
The new product, efanesoctocog alfa (Altuviiio), is a long-acting factor VIII replacement that needs to be given only once weekly.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 24, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB
STOCKHOLM, Feb. 24, 2023 -- (Healthcare Sales & Marketing Network) -- Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], a first-... Biopharmaceuticals, FDA Swedish Orphan Biovitrum, efanesoctocog alfa, factor VIII, haemophilia A (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 24, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Weekly Factor Therapy for Hemophilia A
(MedPage Today) -- The FDA has approved the recombinant antihemophilic factor Fc-VWF-XTEN fusion protein-ehtl (Altuviiio) for the treatment of adults and children with hemophilia A, Sanofi announced on Thursday.
The first-in-class factor VIII... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 24, 2023 Category: Hematology Source Type: news
Sanofi, poised to rival Roche in hemophilia, nabs FDA approval for Altuviiio
Sanofi and partner Sobi are coming back to the hemophilia A market with a vengeance after Roche’s Hemlibra ate up sales of their aging Eloctate. | Sanofi and partner Sobi are coming back to the hemophilia A market with a vengeance after Roche’s Hemlibra ate up sales of their aging Eloctate. The…#rocheshemlibra #eloctate #altuviiio (Source: Reuters: Health)
Source: Reuters: Health - February 24, 2023 Category: Consumer Health News Source Type: news
FDA Approves Altuviiio ([Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]) Once-Weekly VIII Therapy for Hemophilia A
Paris and Stockholm– February 23, 2023– The U.S. Food and Drug Administration (FDA) has approved Altuviiio™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 23, 2023 Category: Drugs & Pharmacology Source Type: news
Gene Tx Shows Sustained Bleeding Control in Severe Hemophilia A at 2 Years
(MedPage Today) -- A single infusion of the gene therapy valoctocogene roxaparvovec led to significantly reduced bleeding rates that persisted in men with severe hemophilia A, 2-year results from the phase III GENEr8-1 trial showed.
Among 112... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 23, 2023 Category: Hematology Source Type: news
Hemophilia A Gene Therapy Durable at 2 Years; Under FDA Review Hemophilia A Gene Therapy Durable at 2 Years; Under FDA Review
Despite an anticipated price tag of $2.5 million, there ' s no way to predict who will have long-standing benefit from valoctocogene roxaparvovec and who will not.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Efanesoctocog Alfa Treatment'Victory' for Hemophilia A Patients Efanesoctocog Alfa Treatment'Victory' for Hemophilia A Patients
A once-weekly prophylactic treatment of this investigational agent led to normal or near-normal factor VIII activity levels in most patients with severe hemophilia A.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Europe Approves First Gene Therapy for Hemophilia B Europe Approves First Gene Therapy for Hemophilia B
The European Commission has approved etranacogene dezaparvovec (Hemgenix), the first gene therapy for severe and moderately severe hemophilia B (congenital factor X1 deficiency).International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
When Launched, Gene Therapy Roctavian Will Be Administered Mainly In 340B-Eligible Treatment Centers, Where It Will Be Substantially Discounted In Price
If approved, the gene therapy Roctavian will likely launch at a list price of ~$2.5 million. But experts anticipate considerable discounts in most instances of sales, as many hemophilia A patients will have the product administered in a 340B-eligible treatment center, at a 340B discounted price. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 16, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
